<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250513065709N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-03</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>The effect of whole body electrical muscle stimulation on spinal diseases</public_title>
      <acronym></acronym>
      <scientific_title>Exploring the Role of Whole Body Electrical Muscle Stimulation in Weight Loss and Functional Enhancement for Individuals with Degenerative Joint Diseases of the Spine and Limited Physical Activity and High Body Mass Index</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>108</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83524</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The randomization process will be performed using random number generation software. In this regard, each eligible patient will be assigned a unique identification code to maintain confidentiality and facilitate unbiased randomization. Randomization will be performed using a random block design with variable size to ensure balance of group sizes throughout the study. Participants will be randomly assigned to one of the following three parallel groups: control group (CG), isometric exercise group (ISO) with isometric exercises and wearing a WB-EMS garment without electrical stimulation, and isometric exercise plus electromyostimulation (ISO + EMS) group with isometric exercises and wearing a WB-EMS garment with electrical stimulation, Blinding description: This study employs a single-blind design where outcome assessors and data collectors are blinded to group allocation, while participants acannot be blinded due to the nature of the intervention. Participants are aware of their group assignment as they can distinguish between receiving electrical stimulation (ISO + EMS group) versus wearing the WB-EMS suit without stimulation (ISO group) or no intervention (control group). However, outcome assessors who conduct anthropometric measurements, questionnaire administration, and functional tests (6MWT, Two-Stage Treadmill Test) are completely blinded to group allocation and will not have access to randomization records. Data collectors responsible for recording measurements and questionnaire responses are also blinded to treatment assignment. The statistical analyst will remain blinded to group allocation during data analysis until the final interpretation phase.</study_design>
      <phase>3</phase>
      <hc_freetext>Neurodegenerative Spine Diseases.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Participants only receive standard care including education on ergonomic principles and spinal care, light stretching and strengthening exercise program appropriate to patient condition, nutritional counseling for weight management, and regular follow-up by the treatment team without any electrical muscle stimulation intervention. Intervention 2: Intervention group 1: Isometric Exercise Group (ISO): Participants wear WB-EMS suits without electrical stimulation and perform supervised isometric exercises twice weekly on non-consecutive days for 30 minutes per session over 8 weeks, including 20 minutes of main training with 6-second contraction and 4-second rest intervals, plus 5-minute warm-up and cool-down periods with stretching movements. Intervention 3: Intervention group 2: Isometric Exercise + Electromyostimulation Group (ISO + EMS): Participants wear WB-EMS suits with electrical stimulation and perform the same supervised isometric exercise protocol as the ISO group, with electrical stimulation intensity progressing from 60% of maximum tolerable stimulation (MT1) during weeks 1-4, to 70% MT1 during weeks 5-6, and 80% MT1 during weeks 7-8, using 85 Hz frequency and 350 microsecond pulse width.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Karimabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Gharani</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7619813159</zip>
        <telephone>+98 34 3226 5433</telephone>
        <email>Rkarimabadi09@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Karimabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Gharani</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7619813159</zip>
        <telephone>+98 34 3226 5433</telephone>
        <email>Rkarimabadi09@gmail.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Degenerative spinal disease diagnosed clinically and according to radiologic findings
Patients with limited mobility to perform activities according to the WIQ index (Score &lt;45)
Aged 50-79 years old
Ability to understand and implement intervention instructions
BMI equal to or greater than 30 kg/m2
Willingness to participate and signing an informed consent form</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>79 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Established neuromuscular disease
Established psychiatric disorders
Diagnosed balance disorders and vertigo
History of spinal surgery in the past 6 months
Severe or uncontrolled cardiovascular disease, including uncontrolled blood pressure (systolic blood pressure &gt; 180 mmHg or diastolic &gt; 110 mmHg) or uncontrolled diabetes (HbA1c &gt; 8%).
Pregnancy or breastfeeding.
Use of anticoagulants.
Presence of metal implants in the body (except dental implants).
Presence of red flags of back pain in patients.
Presence of advanced degenerative knee disease
Failure to continue training within eight weeks and willingness to withdraw from the study (Dropping)
Active rheumatic diseases (such as rheumatoid arthritis, lupus, ankylosing spondylitis) that are not under control</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G32.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Subacute combined degeneration of spinal cord in diseases classified elsewhere</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Participants only receive standard care including education on ergonomic principles and spinal care, light stretching and strengthening exercise program appropriate to patient condition, nutritional counseling for weight management, and regular follow-up by the treatment team without any electrical muscle stimulation intervention.</i_keyword>
      <i_keyword>Intervention group 1: Isometric Exercise Group (ISO): Participants wear WB-EMS suits without electrical stimulation and perform supervised isometric exercises twice weekly on non-consecutive days for 30 minutes per session over 8 weeks, including 20 minutes of main training with 6-second contraction and 4-second rest intervals, plus 5-minute warm-up and cool-down periods with stretching movements.</i_keyword>
      <i_keyword>Intervention group 2: Isometric Exercise + Electromyostimulation Group (ISO + EMS): Participants wear WB-EMS suits with electrical stimulation and perform the same supervised isometric exercise protocol as the ISO group, with electrical stimulation intensity progressing from 60% of maximum tolerable stimulation (MT1) during weeks 1-4, to 70% MT1 during weeks 5-6, and 80% MT1 during weeks 7-8, using 85 Hz frequency and 350 microsecond pulse width.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Walking Impairment Questionnaire (WIQ) Score. Timepoint: Baseline and 8 weeks. Method of measurement: Standardized Walking Impairment Questionnaire (WIQ) questionnaire.</prim_outcome>
      <prim_outcome>Low Back Pain Intensity. Timepoint: baseline and 8 weeks. Method of measurement: Numerical Rating Scale (NRS).</prim_outcome>
      <prim_outcome>Health-Related Quality of Life. Timepoint: baseline and 8 weeks. Method of measurement: Short Form-36 questionnaire (SF-36).</prim_outcome>
      <prim_outcome>6-Minute Walk Test Distance. Timepoint: baseline and 8 weeks. Method of measurement: Measured as total distance walked in meters over 6 minutes on flat 30-meter course.</prim_outcome>
      <prim_outcome>Two-Stage Treadmill Test Duration. Timepoint: baseline and 8 weeks. Method of measurement: Measured as walking time in seconds during second stage at 3 km/h with 10% incline.</prim_outcome>
      <prim_outcome>Anthropometric Measures. Timepoint: baseline and 8 weeks. Method of measurement: BMI, waist Circumference, and hip Circumference will be measured by standardized meter and scale.</prim_outcome>
      <prim_outcome>Body Composition. Timepoint: baseline and 8 weeks. Method of measurement: segmental direct multi-frequency bioelectrical impedance analysis.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-11</approval_date>
        <contact_name>Research Ethics Committees of Afzalipour Hospital- Kerman University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, Kerman University of Medical Sciences, Kerman, Jahad Street, Somayeh Crossroads, Kerman Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
